Navigation Links
Rutgers, UMDNJ research provides unprecedented insight into fighting viral infections
Date:9/29/2011

Researchers at Rutgers and UMDNJ-Robert Wood Johnson Medical School have determined the structure of a protein that is the first line of defense in fighting viral infections including influenza, hepatitis C, West Nile, rabies, and measles.

Principal investigators of the study, "Structural basis of RNA recognition and activation by innate immune receptor RIG-I," chosen for advanced online publication in Nature, say the research is key in the development of broad-based drug therapies to combat viral infections.

"Understanding innate immunity to viral infections is crucial to developing drugs that can fight viruses or control inflammation," said Joseph Marcotrigiano, assistant professor of chemistry and chemical biology at Rutgers who along with Smita Patel, professor of biochemistry at Robert Wood Johnson Medical School, are principal investigators on the newly released study. "Having this foundation is extremely important."

RIG-I is a receptor protein that recognizes differences in molecular patterns in order to differentiate viral RNA the process during which virus particles makes new copies of themselves within a host cell and can then infect other cells -- from cellular RNA. What researchers discovered is that viral RNA, as opposed to single-stranded cellular RNA, is a double-stranded structure. This double-stranded difference is the reason the RIG-I protein recognizes it and initiates a signal to induce anti-immune and anti-inflammatory defenses within the cell.

Prior to this research, there was little information on how RIG-I protein recognized the viral infections, said Patel. "A failure of RIG-I to identify viral RNA can lead to alterations of the cell, including cell death, inflammation, autoimmune diseases, and cancer," he said.

This is a first step, the scientists say, in helping to develop therapies that interfere with a broad variety of viral infections a major breakthrough for millions of people
'/>"/>

Contact: Robin Lally
rlally@ur.rutgers.edu
732-932-7084 x652
Rutgers University
Source:Eurekalert

Page: 1 2

Related biology news :

1. Rutgers, UMDNJ receive $23 million to develop antidotes for chemical weapons attacks
2. TAXIS Pharmaceuticals licenses novel antimicrobial technology from Rutgers and UMDNJ
3. Woody biomass research grant to launch biofuel industry in the Pacific Northwest
4. Lawson research shows Canadians dont believe their eyes
5. Salk scientist receives distinguished NIH award for transformative research
6. Research solutions for sustainability in a rapidly changing world
7. Stanford Precourt Institute and TomKat Center award energy research grants
8. RIKEN OSC and Kitasato University sign joint research agreement
9. Europe punches above its weight in biomedical research, despite limited funding
10. Dead Sea researchers discover freshwater springs and numerous micro-organisms
11. Eating balanced meals, farm-fresh produce benefits families, communities, nutrition researchers say
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/8/2014)... OhioThe future health of the world,s coral reefs and ... on the ability of one tiny symbiotic sea creature ... of algae it cooperates with. , In the first ... University discovered that coralstiny reef-forming animals that live symbiotically ... of heat stress, called "bleaching," when they keep large ...
(Date:7/8/2014)... Think of your next exercise workout as a "fun run" or ... of it as exercise or as a workout and you,ll later ... findings from the Cornell Food and Brand Lab study involved two ... a small lake and were either told it was going to ... the first study, 56 adults completed their walk and were then ...
(Date:7/8/2014)... NY, July 8, 2014Novel oligonucleotide-based drugs in development ... diseases. A group of industry and regulatory scientists ... recommendations for evaluating the pharmacological safety of oligonucleotide ... Acid Therapeutics , a peer-reviewed journal from Mary ... on the Nucleic Acid Therapeutics ...
Breaking Biology News(10 mins):For corals adapting to climate change, it's survival of the fattest -- and most flexible 2For corals adapting to climate change, it's survival of the fattest -- and most flexible 3For corals adapting to climate change, it's survival of the fattest -- and most flexible 4
... issue of G&D report on the discovery of ... The studies from Drs. Alexander Stark and Manolis ... Lai (MSKCC) and colleagues, both reveal that antisense ... the novel miRNA precursor mir-iab-8, which is processed ...
... doctors treating life-threatening emergencies such as allergy attacks may give ... Adrenaline is stored in salt water in glass ampoules ... The amount of adrenaline contained in the ampoule is usually ... per 1 mL of salt water) and a ratio (1 ...
... team at Weill Cornell Medical College in New York City ... production of an immune system cytokine called interleukin-10 (IL-10). ... in a biochemical pathway that,s long been tied to disorders ... AIDS. "IL-10 production has to be kept in a ...
Cached Biology News:Doctors may be giving the wrong dosage of adrenaline in an emergency because of labelling 22 genes are important key to regulating immune response 22 genes are important key to regulating immune response 3
(Date:1/15/2014)... (PRWEB) January 15, 2014 2013 was ... Scottsdale’s Brain State Technologies®. They saw continued independent research ... Center who were awarded a $1 million grant from ... in “Brain and Behavior” a peer reviewed journal, Amy ...
(Date:1/15/2014)... TaiGen Biotechnology Company, Limited ("TaiGen") today announced that ... leading Russian pharmaceutical company, to develop and commercialize nemonoxacin ... , Turkey and other ... novel antibiotic for the treatment of bacterial infections including ...
(Date:1/14/2014)... Histogen, Inc., a regenerative medicine company developing ... simulated embryonic conditions, today announced that they have entered ... for physician-dispensed aesthetic products containing Histogen’s proprietary multipotent cell ... an amendment to the existing license between Histogen and ...
(Date:1/14/2014)... New York, NY (PRWEB) January 14, 2014 ... coverage of Alliqua, Inc. (OTCQB: ALQA). Alliqua is an ... products to serve the wound care market. , Free ... Alliqua was restructured with a seasoned management team and ...
Breaking Biology Technology:Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 2Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3
... at the University of Central Florida have developed a ... more sensitive tool to detect pathogens associated with inflammatory ... nanoparticle-based technique also may be used for detection of ... they hide deep in human tissue and are able ...
... 2012 Genesis Biopharma, Inc. (OTCBB: GNBP), a biotechnology company ... offer shares of its common stock and warrants to purchase ... The offering is subject to market and other conditions, and ... the offering may be completed, or as to the actual ...
... wholly owned subsidiary of British company Innovative Carbon Limited today ... 10th April to 13th. , Graphene, a sheet of carbon ... wonder material. First isolated at Manchester University in 2004, ... race has been on to produce it commercially. To ...
Cached Biology Technology:UCF scientists use nanotechnology to hunt for hidden pathogens 2Genesis Biopharma Announces Proposed Public Offering of Common Stock and Warrants 2Genesis Biopharma Announces Proposed Public Offering of Common Stock and Warrants 3UK company to demonstrate their commercially effective graphene production process 2